Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Kura Oncology at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Kura Oncology exhibits at Booth 2229 at ASH 2026 in New Orleans. Kura Oncology supports symposia on acute myeloid leukemia, with a focus on precision treatment and second-opinion review of patient cases. The most specific looks at how menin inhibitors fit into precision care for the disease.

OrganizationASH 2026 Attendance
Kura Oncology
San Diego, CA
Biotech
Precision oncology company developing ziftomenib, a menin inhibitor for acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements, and other targeted cancer drugs.
Booth
Exhibiting at Booth 2229
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
7:00am–10:00am
Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review
Difficult acute myeloid leukemia cases where doctors sought second opinions, paired with reviews of recent data, current management, and ongoing trials.
Leukemias
Symposium
Fri Dec 11
3:00pm–6:00pm
Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia With the Integration of Menin Inhibitors
Menin inhibitors for genetically defined acute myeloid leukemia, covering patient selection, combinations, resistance, and differentiation syndrome.
Leukemias · New drugs

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Kura Oncology

Tell us what you sell and we’ll find the people at Kura Oncology most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction